On May 20, the third-generation central nervous system calcium channel regulator Kligabalin was officially approved by the State Drug Administration for clinical treatment of diabetes related peripheral neuropathic pain (DPNP). According to epidemiological data statistics, there are approximately 37 million patients with DPNP in China, but the large population of patients is unable to overcome pain problems due to the lack of targeted treatment drugs, which is undoubtedly a huge dilemma. DPNP is the abbreviation of diabetes peripheral neuropathic pain (DPNP), which is also called "sugar pain" in the mouth of patients. As one of the serious complications of diabetes, DPNP is mainly manifested as burning like, acupuncture like, tearing like, jumping like, electric shock like, knife cutting like and compression like pain with continuous or intermittent attacks. Once found, it not only seriously affects the quality of life of patients, but also may lead to dysfunction or even disability. Its treatment has gradually become the focus of attention in the global medical field. Since its launch in 1993, the first generation of central nervous system calcium channel regulators have faced problems such as complex titration processes, slow onset of action, and significant adverse reactions, which have caused many difficulties for patients. Faced with such problems, Hisilicon Pharmaceutical Group decisively launched the research and development project of drugs for the treatment of neuropathic pain in 2014. The goal is to discover a novel molecule that can overcome the shortcomings of the previous two generations of drugs, while improving treatment efficacy and safety, and providing substantial therapeutic support for DPNP patients. After ten years of unremitting efforts, including countless screening, in-depth research, and repeated experiments, Kligabalin has finally been born and has passed strict clinical validation in Phase I/II/III. (Lai Xin She)